Methods to improve the immunogenicity of plasmid DNA vaccines

被引:56
|
作者
Eusebio, Dalinda [1 ]
Neves, Ana R. [1 ]
Costa, Diana [1 ]
Biswas, Swati [2 ]
Alves, Gilberto [1 ]
Cui, Zhengrong [3 ]
Sousa, Angela [1 ]
机构
[1] Univ Beira Interior, CICS UBI Hlth Sci Res Ctr, Av Infante D Henrique, P-6200506 Covilha, Portugal
[2] Birla Inst Technol & Sci Pilani, Dept Pharm, Hyderabad Campus, Hyderabad 500078, Telangana, India
[3] Univ Texas Austin, Coll Pharm, Div Mol Pharmaceut & Drug Delivery, Austin, TX 78712 USA
关键词
Adjuvants; Administration routes; Delivery systems; Immunogenicity; Plasmid DNA vaccines; MINICIRCLE DNA; IMMUNE-RESPONSE; INTRAMUSCULAR ELECTROPORATION; PROTECTIVE EFFICACY; VIRUS; DELIVERY; GENE; VACCINATION; CHITOSAN; MECHANISMS;
D O I
10.1016/j.drudis.2021.06.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
DNA vaccines have emerged as innovative approaches that have great potential to overcome the limitations of current conventional vaccines. Plasmid DNA vaccines are often safer than other vaccines because they carry only antigen genetic information, are more stable and easier to produce, and can stimulate both humoral and cellular immune responses. Although the results of ongoing clinical trials are very promising, some limitations compromise the immunogenicity of these vaccines. Thus, this review describes different strategies that can be explored to improve the immunogenicity of plasmid DNA vaccines, including the optimization of the plasmid vector backbone, the use of different methods for vaccine delivery, the use of alternative administration routes and the inclusion of adjuvants. In combination, these improvements could lead to the successful clinical use of plasmid DNA vaccines.
引用
收藏
页码:2575 / 2592
页数:18
相关论文
共 50 条
  • [21] EFFICACY AND IMMUNOGENICITY OF DNA VACCINES FOR VIRAL DISEASES
    LIU, MA
    ULMER, J
    SHIVER, J
    FRIEDMAN, A
    MCCLEMENTS, W
    DONNELLY, J
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 278 - 278
  • [22] Methods for improving the immunogenicity and efficacy of cancer vaccines
    Pilla, Lorenzo
    Ferrone, Soldano
    Maccalli, Cristina
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (07) : 765 - 784
  • [23] METHODS OF EVALUATING IMMUNOGENICITY OF MYCOBACTERIAL VACCINES AND FRACTIONS
    WIEGESHAUS, E
    GROVER, AA
    SMITH, DW
    ZEITSCHRIFT FUR IMMUNITATS-FORSCHUNG ALLERGIE UND KLINISCHE IMMUNOLOGIE, 1969, 137 (1-3): : 94 - +
  • [24] Plasmid DNA vaccines are effective in the absence of IFNγ
    Hassett, DE
    Zhang, J
    Whitton, JL
    VIROLOGY, 1999, 263 (01) : 175 - 183
  • [25] Influenza Plasmid DNA Vaccines: Progress and Prospects
    Bicho, Diana
    Queiroz, Joao Antonio
    Tomaz, Candida Teixeira
    CURRENT GENE THERAPY, 2015, 15 (06) : 541 - 549
  • [26] Plasmid DNA-Based Alphavirus Vaccines
    Lundstrom, Kenneth
    VACCINES, 2019, 7 (01):
  • [27] Human clinical trials of plasmid DNA vaccines
    Liu, Margaret A.
    Ulmer, Jeffrey B.
    ADVANCES IN GENETICS, 2005, 55 : 25 - 40
  • [28] Plasmid based DNA vaccines against tuberculosis
    Shahzad, M. I.
    Khan, I.
    Khanum, A.
    Luciw, P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : S22 - S23
  • [29] Plasmid DNA vaccines: where are we now?
    Ghaffarifar, F.
    DRUGS OF TODAY, 2018, 54 (05) : 315 - 333
  • [30] Plasmid DNA vaccines - Immunology, tolerance, and autoimmunity
    Mor, G
    Eliza, M
    MOLECULAR BIOTECHNOLOGY, 2001, 19 (03) : 245 - 250